Table 2.

Correlation of the expression of the two candidate miRNA and clinical features of SLE

Clinical characteristics	N	NovelmiRNA-25	P	all-hsa-miR-1273h-5p	P
Leukocyte
< 3.5	2	0.39 ± 0.12	0.045	1.50 ± 0.67	0.452
3.5–9.5	16	5.80 ± 5.38		2.78 ± 2.00
> 9.5	3	0.64 ± 0.25		1.89 ± 1.02
Neutrophil
1.8–6.3	15	6.06 ± 5.48	0.002	2.91 ± 2.01	0.271
> 6.3	4	0.78 ± 0.34		1.72 ± 0.90
Albumin
< 40	14	4.89 ± 4.85	0.034	2.98 ± 1.98	0.748
40–55	1	16.81		3.65
C3
< 0.79	15	5.67 ± 5.74	0.019	2.86 ± 2.04	0.173
0.79–1.52	7	1.55 ± 1.61		1.73 ± 0.72
C4
< 0.16	17	4.68 ± 5.76	0.524	1.75 (1.15, 2.57)	0.031
0.16–0.38	4	2.74 ± 2.12		3.91 (2.45, 6.17)
Lupus anticoagulant
0.75–1.25	10	3.65 ± 5.57	0.561	2.11 ± 1.24	0.034
> 1.25	3	5.62 ± 4.57		4.58 ± 2.50
24 h urine protein
< 0.5	3	8.65 ± 8.17	0.074	4.36 ± 2.80	0.073
> 0.5	9	2.80 ± 2.73		2.11 ± 1.25
Alanine aminotransferase
7–40	14	5.36 ± 5.96	0.984	2.79 ± 1.98	0.61
> 40	2	5.45 ± 0.03		3.57 ± 1.96
Anti-ds-DNA antibody
Positive	12	1.99 (0.53, 6.59)	0.75	1.64 (1.07, 4.62)	0.553
Negative	6	2.10 (0.73, 11.75)		1.64 (1.07, 4.62)

C3/C4 complement 3/complement 4